Message from the President - Volume 21, Issue

Dear Medical Writers Top of Form Bottom of Form The last time I wrote to you I briefly introduced myself and outlined some of the plans that I hope to realise during my year as president. However, as president I am only one of the members of the…

About the Medical Writing Journal - Volume 21, Issue

The official journal of the European Medical Writers Association (EMWA) has changed its name from The Write Stuff to Medical Writing, which is being published by Maney Publishing. This marks a leap forward for the journal, which is now in its 19th…

Regulatory Writing Basics - Volume 23, Issue

Post-Approval Regulatory Writing - Volume 23, Issue

Regulatory Public Disclosure - Volume 29, Issue

Activities around clinical documents disclosure have been slow since September 2018 when I last published this section. As many of you receive emails from the CORE Reference website (sign up at https://www.core-reference.org/subscribe), you have…

Regulatory Public Disclosure - Volume 33, Issue

Section Editor and Author: Sam Hamilton   Medical Writing. 2024;33(3):95–100. https://doi.org/10.56012/vhdv1639

Good Writing Practice - Volume 28, Issue

The repetition of a word becomes more distracting (i.e., redundant) in proportion to increased number. The word may be considered as individual (e.g., the’s in a title) or as a constituent of a larger syntactic unit (a phrase or clause).

HTA decision-making: Do ethics matter? - Volume 30, Issue

Before reviewing the article in this issue of Medical Writing by Larry Liberti and Tina Wang, The regulatory-HTA decision-making interface: What the medical writer should know (p. 50), I put on my ethicist’s hat. Thus, I tuned my ethics antennae to…

The Webscout - Volume 21, Issue

Cannabinoids in oncology: more than a palliative Usually you have chemotherapeutics and biologicals in mind when you are talking about oncology. Would you have thought of cannabinoids? I don't think so but for decades, cannabinoids have been known…

Essential investments in optimising clinical research for rare disease - Volume 34, Issue

The complexities associated with clinical trials for (ultra) rare diseases include regulatory and logistical hurdles and the challenge of building trusting relationships with health authorities, patients, and clinicians. Significant obstacles…